Acquired resistance to T cell adoptive transfer by inflammation-induced melanoma dedifferentiation.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 3047-3047 ◽  
Author(s):  
Arnav Mehta ◽  
Yeon Joo Kim ◽  
Lidia Robert ◽  
Begonya Comin-Anduix ◽  
Beata Berent-Maoz ◽  
...  
2020 ◽  
Vol 70 (1) ◽  
pp. 16-24
Author(s):  
Charlie C Hsu ◽  
Karuna Patil ◽  
Audrey Seamons ◽  
Thea L Brabb ◽  
Piper M Treuting ◽  
...  

Murine norovirus (MNV) infection is highly prevalent in laboratory mice. Although MNV infection does not typically induce clinical disease in most laboratory mice, infection may nonetheless affect mouse models of disease by altering immune responses. We previously reported that MNV altered the bacterial-induced mouse model of inflammatory bowel disease (IBD) using Helicobacter-infected Mdr1a–/– mice. Therefore, we hypothesized that MNV infection would exacerbate another mouse model of IBD, the T-cell adoptive transfer (AT) model. In this model, Helicobacter infection is used to accelerate the progression of IBD induced by AT of naïve CD4+CD45RBhigh T cells into B6.129S7- Rag1tm1Mom/J (Rag1–/–) mice. We evaluated the effects of MNV infection in both Helicobacter-accelerated as well as Helicobacter-free AT models. In our studies, Helicobacter-infected Rag1–/– mice that received CD4+CD45RBhigh T cells through AT rapidly developed weight loss and typhlocolitis; MNV infection had no effect on disease severity or rate of progression. In the absence of Helicobacter infection, progression of IBD caused by AT of CD4+CD45RBhigh T cells was slower and typhlocolitis was less severe; this inflammation likewise was unaltered by MNV infection. These results indicate that MNV infection does not alter IBD progression and severity in the CD4+CD45RBhigh T-cell AT model in Rag1–/– mice.


2011 ◽  
Vol 186 (6) ◽  
pp. 3327-3335 ◽  
Author(s):  
Maria Salagianni ◽  
Eftychia Lekka ◽  
Ardiana Moustaki ◽  
Eleni G. Iliopoulou ◽  
Constantin N. Baxevanis ◽  
...  

2013 ◽  
Vol 4 ◽  
Author(s):  
Gozlan Yosi ◽  
Alteber Zoya ◽  
Azulay Meir ◽  
Sharbi Yunger Adi ◽  
Tzehoval Esther ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Estéfani García-Ríos ◽  
Marcos Nuévalos ◽  
Francisco J. Mancebo ◽  
Pilar Pérez-Romero

During the last decade, many studies have demonstrated the role of CMV specific T-cell immune response on controlling CMV replication and dissemination. In fact, it is well established that transplanted patients lacking CMV-specific T-cell immunity have an increased occurrence of CMV replication episodes and CMV-related complications. In this context, the use of adoptive transfer of CMV-specific T-cells has been widely investigated and applied to Hematopoietic Stem Cell Transplant patients and may be useful as a therapeutic alternative, to reconstitute the CMV specific T-cell response and to control CMV viremia in patients receiving a transplantation. However, only few authors have explored the use of T-cell adoptive transfer in SOT recipients. We propose a novel review in which we provide an overview of the impact of using CMV-specific T-cell adoptive transfer on the control of CMV infection in SOT recipients, the different approaches to stimulate, isolate and expand CMV-specific T-cells developed over the years and a discussion of the possible use of CMV adoptive cellular therapy in this SOT population. Given the timeliness and importance of this topic, we believe that such an analysis will provide important insights into CMV infection and its treatment/prevention.


Sign in / Sign up

Export Citation Format

Share Document